Become a Member to Save

LIVTENCITY▼® (maribavir) dosing summary

LIVTENCITY (maribavir) is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).1
Consideration should be given to official guidance on the appropriate use of antiviral agents.1

This is only a summary for the dosing of LIVTENCITY, please consult the Summary of Product Characteristics for LIVTENCITY before prescribing.

In the pivotal Phase 3 trial, LIVTENCITY delivered double the viraemia clearance (55.7%) compared to investigator-assigned therapy (IAT) (23.9%) – primary endpoint2

Confirmed viraemia clearance* of refractory/resistant CMV in all transplants (HSCT and SOT) at Study Week 82

*Plasma CMV DNA <137 IU/mL in 2 consecutive tests ≥5 days apart.2

Prescribing LIVTENCITY (maribavir) summary

Twice-daily oral administration

  • The recommended dose of LIVTENCITY is 400 mg (two 200 mg tablets) twice daily resulting in a daily dose of 800 mg for 8 weeks1
  • LIVTENCITY is an oral treatment that can be taken at home by a patient1
  • LIVTENCITY can be taken with or without food. The tablet can be taken as a whole tablet, a crushed tablet, or a crushed tablet through a nasogastric or orogastric tube1
  • Patients should be instructed that if they miss a dose of LIVTENCITY, and the next dose is due within the next 3 hours, they should skip the missed dose and continue with the regular schedule. Patients should not double their next dose or take more than the prescribed dose1

LIVTENCITY should be initiated by a physician experienced in the management of patients who have undergone SOT or HSCT.1